Supportive Care in Cancer

, Volume 15, Issue 9, pp 1023–1033

A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis

Authors

    • Department for Hematology/OncologyMartin-Luther University Halle/Wittenberg
  • A. Hinke
    • WiSP
  • A. Grothey
    • Mayo Clinic
  • W. Voigt
    • Department for Hematology/OncologyMartin-Luther University Halle/Wittenberg
  • D. Arnold
    • Department for Hematology/OncologyMartin-Luther University Halle/Wittenberg
  • H.-H. Wolf
    • Department for Hematology/OncologyMartin-Luther University Halle/Wittenberg
  • H.-J. Schmoll
    • Department for Hematology/OncologyMartin-Luther University Halle/Wittenberg
Review Article

DOI: 10.1007/s00520-006-0186-7

Cite this article as:
Jordan, K., Hinke, A., Grothey, A. et al. Support Care Cancer (2007) 15: 1023. doi:10.1007/s00520-006-0186-7

Abstract

Goals of work

Comparing antiemetic efficacy of different 5-HT3-receptor antagonists (5-HT3RAs) is difficult due to inter-study variability. Therefore, a meta-analysis was performed to comparatively evaluate dolasetron, granisetron, ondansetron and tropisetron for acute chemotherapy-induced nausea and vomiting (CINV).

Patients and methods

Comparisons between 5-HT3RAs were based on 44 randomized studies (including 12,343 patients) identified by MEDLINE, CANCERLIT or EMBASE searches and subcategorized by chemotherapy type (cisplatin- or non-cisplatin-based).

Main results

When all studies were combined, granisetron was equivalent to ondansetron (n = 27), and showed an advantage vs tropisetron (p = 0.018; n = 12). Ondansetron vs tropisetron (n = 11) and ondansetron vs dolasetron (n = 3) revealed equivalence in each comparison. An advantage for 3 mg granisetron vs 8 mg ondansetron was found in non-cisplatin-based studies (p = 0.015; n = 6). Overall equivalence was seen between ondansetron, 24 or 32 mg, and granisetron, 2 or 3 mg, for all studies (n = 13). There was a possible advantage for higher (24 or 32 mg) vs lower (8 mg) ondansetron dose regimens with cisplatin-based trials (n = 6). No differences were seen between 3 and 1 mg granisetron doses (n = 6).

Conclusions

Efficacy of 5-HT3RAs for preventing CINV following cisplatin- and non-cisplatin-based chemotherapy is comparable, with the exception of granisetron vs tropisetron. Some differences were noted in dosing subanalyses.

Keywords

AntiemeticChemotherapyDosing regimensEfficacy5-HT3RAs

Copyright information

© Springer-Verlag 2007